Printer Friendly

WHITEHALL LABORATORIES REAFFIRMS ITS COMMITMENT TO CHILD RESISTANT CLOSURES

 WHITEHALL LABORATORIES REAFFIRMS ITS COMMITMENT
 TO CHILD RESISTANT CLOSURES
 NEW YORK, June 11 /PRNewswire/ -- Whitehall Laboratories the makers of Advil(R) ibuprofen, reaffirms its commitment to child resistant closures (CRC) for over-the-counter analgesics.
 Existing Consumer Product Safety Commission regulations mandate CTC's on all acetaminophen or aspirin containing analgesics. New regulations will extend the CRC requirements to OTC ibuprofen products as well.
 Since the approval of Advil in 1984, Whitehall Laboratories has voluntarily provided child resistant closures on Advil. We are in full agreement with CPSC regulations regarding CRC's.
 However, we believe it is important that discussion of these regulations should also emphasize the superior safety record of ibuprofen in overdose.
 Extensive data show that non-prescription ibuprofen is the safest of all non-prescription analgesics if taken in overdose. The superior safety profile of ibuprofen in accidental and/or intentional overdose was cited by FDA compared to aspirin and acetaminophen products, e.g., Tylenol(R), Aspirin-Free Anacin(R), Aspirin-Free Excedrin(R), when it approved non-prescription ibuprofen in 1984.
 In 1990, the most recent year for which data are available, acetaminophen products and aspirin products were associated with substantially more deaths, as shown below:
 Total Major
 Drug Exposures Deaths Outcome(C)
 Acetaminophen Only 82,089 34 148
 Aspirin Only 16,640 37 92
 Ibuprofen-OTC 21,792(A) 0 28
 Ibuprofen-RX 5,886 1(B) 16
 Source: 1990 annual report of the American Association of Poison Control Centers National Data Collection System.
 (A) Numbers include 5,420 unknown (exposures where it could not be determined whether Rx or OTC).
 (B) Intentional suicide by adult, which also included another more toxic drug.
 (C) Major outcome is defined as symptoms, which were life- threatening, or resulted in disfigurement or residual disability.
 The majority of ibuprofen overdoses do not result in significant toxicity, and typically require no complex medical intervention.
 While most cases of OTC analgesics overdose do not produce significant toxicity, life-threatening symptoms can occur more frequently with acetaminophen or aspirin overdose, compared to ibuprofen.
 -0- 6/11/92
 /CONTACT: Karen Richards of Whitehall Laboratories, 212-878-6923/ CO: Whitehall Laboratories ST: New York IN: MTC SU:


PS-SM -- NY039 -- 9193 06/11/92 11:15 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 11, 1992
Words:358
Previous Article:VOLT INFORMATION SCIENCES ANNOUNCES SECOND QUARTER AND SIX MONTHS 1992 RESULTS OF OPERATIONS
Next Article:HYATT REGENCY TO RENAME ATRIUM LOBBY FOR SILVER ANNIVERSARY
Topics:


Related Articles
AMERICAN HOME PRODUCTS AND ELI LILLY AND COMPANY ANNOUNCE MARKETING AGREEMENT
AMERICAN HOME PRODUCTS CORPORATION ANNOUNCES BENEFITS PACKAGE FOR ELKHART WORKERS
JOINT STATEMENT FOR WHITEHALL LABORATORIES AND THE NEW YORK ROAD RUNNERS CLUB ON REPORTS OF ILLNESS AT NEW YORK CITY MARATHON
UNIVERSITY OF IOWA AND LEDERLE LAUNCH FIRST-OF-ITS-KIND NATIONWIDE SURVEILLANCE NETWORK
The Closer(TM), Advanced Vascular Device, Approved for Marketing by FDA.
Clarithromycin (Biaxin(R)) Active Against Anthrax in Vitro; - Data Suggest Low Emergence of Biaxin Resistance In Vitro -.
CPSC Seeks Comment on Child-Resistant Packaging Petition.
Lidocaine and Prilocaine Cream, 2.5%/2.5%(Rx) First Approval Allows Fougera to Meet Health Care Demand.
Abbott Laboratories Announces Launch of Enhanced Perclose A-T(TM); Added Features Include New Suture Trimmer and Numbered Deployment Steps For Ease...
Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters